Target intelligence / Profile preview

Thymocyte selection-associated high mobility group box protein TOX (TOX)

Target
TOX
Molecular classification
Transcription factor, DNA-binding protein, Chromatin regulator
01

Overview

Thymocyte selection-associated high mobility group box protein TOX is a nuclear DNA-binding transcription factor and chromatin regulator belonging to the high mobility group (HMG)-box superfamily. It plays a critical role in the development of various immune cells, including CD4+ T cells, natural killer (NK) cells, and innate lymphoid cells (ILCs). In the context of chronic antigen stimulation, such as in cancer or chronic viral infections, TOX acts as a master regulator of CD8+ T-cell exhaustion by driving transcriptional and epigenetic changes that upregulate inhibitory receptors like PD-1. Additionally, TOX is overexpressed in certain lymphocytic malignancies, such as T-cell acute lymphoblastic leukemia (T-ALL) and cutaneous T-cell lymphoma (CTCL), where it promotes genomic instability and tumor cell survival. Although there are currently no FDA-approved drugs targeting TOX, experimental small molecule inhibitors (such as KI-TOX-A3 and 92778-A3) are being developed to disrupt its DNA-binding or protein-protein interactions, offering a promising therapeutic strategy to reverse T-cell exhaustion and treat hematological malignancies.

Other names
Thymocyte selection-associated high mobility group box proteinThymus high mobility group box protein TOXThymocyte selection-associated HMG box proteinTOX1
02

Mechanism of action

Inhibition of TOX protein-protein interactions (such as with KU70/80 or KAT7) or DNA-binding activity at its HMG-box domain, leading to downregulation of TOX expression, suppression of PD-1 expression, and reversal of T-cell exhaustion.

03

Biological functions

Immune responseT-cell developmentT-cell exhaustionCell differentiationChromatin remodelingTranscription regulation
04

Disease associations

CancerLeukemiaLymphomaInfectionAutoimmune disease
05

Safety considerations

Impaired T-cell developmentAutoimmunityDisruption of innate lymphoid cell (ILC) and natural killer (NK) cell developmentPotential systemic immunotoxicity
06

Interacting drugs

KI-TOX-A3

3 more in the full profile.

07

Biomarkers

TOX expression levelPD-1 expressionH3K14 acetylationT-cell exhaustion markers (TIM-3, LAG-3, TIGIT)

Beyond the preview

Go deeper on Thymocyte selection-associated high mobility group box protein TOX (TOX).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Thymocyte selection-associated high mobility group box protein TOX (TOX).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call